BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2295904)

  • 21. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.
    Barakat RR; Almadrones L; Venkatraman ES; Aghajanian C; Brown C; Shapiro F; Curtin JP; Spriggs D
    Gynecol Oncol; 1998 Apr; 69(1):17-22. PubMed ID: 9570993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Shi T; Jiang R; Yu J; Yang H; Tu D; Dai Z; Shen Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2018 Jul; 119(1):12-18. PubMed ID: 29899395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
    Nardi M; Cognetti F; Pollera CF; Giulia MD; Lombardi A; Atlante G; Calabresi F
    J Clin Oncol; 1990 Jun; 8(6):1036-41. PubMed ID: 2189953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
    Leichman L; Silberman H; Leichman CG; Spears CP; Ray M; Muggia FM; Kiyabu M; Radin R; Laine L; Stain S
    J Clin Oncol; 1992 Dec; 10(12):1933-42. PubMed ID: 1453207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M; Blessing JA; Major F; Manetta A
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
    Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
    Menczer J; Ben-Baruch G; Rizel S; Brenner H
    Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.